{"id":"ophthalmic-emulsion","safety":{"commonSideEffects":[{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Foreign body sensation"},{"rate":null,"effect":"Ocular discomfort"}]},"_chembl":null,"_dailymed":{"setId":"12803630-3196-1b3e-28e4-a598a742ef1a","title":"DIFLUPREDNATE OPHTHALMIC EMULSION (DIFLUPREDNATE OPHTHALMIC) EMULSION [DR. REDDY'S LABORATORIES INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ophthalmic emulsions are oil-in-water or water-in-oil formulations designed to deliver sustained lubrication to dry eyes. They work by coating the ocular surface, reducing tear evaporation, and providing comfort through prolonged contact time. These formulations are particularly effective for moderate to severe dry eye disease where aqueous tear deficiency or meibomian gland dysfunction is present.","oneSentence":"An ophthalmic emulsion that lubricates and protects the ocular surface by providing moisture and forming a protective barrier on the cornea and conjunctiva.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:31.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease / Keratoconjunctivitis sicca"}]},"trialDetails":[{"nctId":"NCT06052956","phase":"PHASE2","title":"Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-07-15","conditions":"Abscess","enrollment":120},{"nctId":"NCT07368595","phase":"PHASE4","title":"Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Dry Eye Disease (DED)","enrollment":60},{"nctId":"NCT06144918","phase":"PHASE2","title":"Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure","status":"COMPLETED","sponsor":"Skye Bioscience, Inc.","startDate":"2023-11-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":56},{"nctId":"NCT07220408","phase":"PHASE2","title":"Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2025-10-23","conditions":"Allergic Conjunctivitis","enrollment":60},{"nctId":"NCT04795752","phase":"NA","title":"Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)","status":"COMPLETED","sponsor":"Sight Sciences, Inc.","startDate":"2021-04-28","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":345},{"nctId":"NCT06886373","phase":"PHASE4","title":"Optimizing the Ocular Surface With Systane COMPLETE Pre- and Post-operatively in Patients With Dry Eye Planning for Cataract Surgery: An Extension Study of Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-03-25","conditions":"Ophthalmology","enrollment":140},{"nctId":"NCT05456425","phase":"PHASE3","title":"A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cloudbreak Therapeutics, LLC","startDate":"2022-06-30","conditions":"Pterygium","enrollment":660},{"nctId":"NCT06903884","phase":"PHASE3","title":"3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-12-30","conditions":"Vernal Keratoconjunctivitis","enrollment":94},{"nctId":"NCT07169695","phase":"PHASE2","title":"A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2026-03-02","conditions":"Moderate to Severe Vernal Keratoconjunctivitis","enrollment":120},{"nctId":"NCT07064187","phase":"PHASE4","title":"Evaluate The Improvement In Symptoms Of Patients Using Cationorm After Pterygium Surgery","status":"COMPLETED","sponsor":"Nguyen Viet Giap","startDate":"2022-06-15","conditions":"Ocular Discomfort","enrollment":100},{"nctId":"NCT04111965","phase":"PHASE1, PHASE2","title":"Clinical Trial to Compare the Safety and Efficacy of Nanodrop®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2020-12-01","conditions":"Dry Eye","enrollment":126},{"nctId":"NCT06443775","phase":"","title":"An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-06-17","conditions":"Dry Eye","enrollment":47},{"nctId":"NCT01013077","phase":"NA","title":"The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2009-11","conditions":"Dry Eye Syndrome","enrollment":20},{"nctId":"NCT04884256","phase":"PHASE2","title":"Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula","status":"COMPLETED","sponsor":"Cloudbreak Therapeutics, LLC","startDate":"2023-12-21","conditions":"Pinguecula","enrollment":88},{"nctId":"NCT04701086","phase":"NA","title":"3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2021-09-30","conditions":"Dry Eye Syndromes","enrollment":83},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT01207752","phase":"NA","title":"The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2010-09","conditions":"Meibomian Gland Dysfunction","enrollment":69},{"nctId":"NCT06174181","phase":"NA","title":"Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2023-10-09","conditions":"Dry Eye Syndromes, Age-Related Macular Degeneration","enrollment":42},{"nctId":"NCT04918823","phase":"PHASE1, PHASE2","title":"Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device","status":"COMPLETED","sponsor":"Boston Sight","startDate":"2021-07-15","conditions":"Ocular Surface Disease","enrollment":10},{"nctId":"NCT06686472","phase":"PHASE2","title":"Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2024-10-03","conditions":"Allergic Conjunctivitis","enrollment":66},{"nctId":"NCT04144413","phase":"PHASE3","title":"3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-05-31","conditions":"Dry Eye Disease With Severe Keratitis","enrollment":350},{"nctId":"NCT06225973","phase":"PHASE2","title":"A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2024-02-06","conditions":"Dry Eye Disease","enrollment":880},{"nctId":"NCT06293820","phase":"PHASE2","title":"A Study Of TL-925 For The Treatment of AC","status":"COMPLETED","sponsor":"Telios Pharma, Inc.","startDate":"2024-04-11","conditions":"Allergic Conjunctivitis","enrollment":80},{"nctId":"NCT06436261","phase":"NA","title":"Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Hybrid-Fractional Laser for Facial Rejuvenation","status":"COMPLETED","sponsor":"Revision Skincare","startDate":"2021-12-14","conditions":"Photoaging, Wrinkle, Skin Laxity","enrollment":20},{"nctId":"NCT04133311","phase":"PHASE3","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-04-10","conditions":"Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease","enrollment":386},{"nctId":"NCT06157853","phase":"NA","title":"Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Radiofrequency Microneedling for Facial Rejuvenation","status":"COMPLETED","sponsor":"Revision Skincare","startDate":"2022-07-11","conditions":"Photoaging, Wrinkle","enrollment":11},{"nctId":"NCT02240498","phase":"PHASE1","title":"Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-09","conditions":"Abscess","enrollment":21},{"nctId":"NCT04357795","phase":"PHASE4","title":"Effect of Cequa™ in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-06-29","conditions":"Dry Eye Disease","enrollment":135},{"nctId":"NCT06153342","phase":"PHASE2","title":"A Study of TL-925 for the Treatment of Allergic Conjunctivitis","status":"UNKNOWN","sponsor":"Telios Pharma, Inc.","startDate":"2023-11","conditions":"Allergic Conjunctivitis","enrollment":70},{"nctId":"NCT05745064","phase":"PHASE2","title":"A Study of TL-925 as a Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Telios Pharma, Inc.","startDate":"2023-02-27","conditions":"Dry Eye Disease","enrollment":107},{"nctId":"NCT04555694","phase":"PHASE4","title":"Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax","status":"COMPLETED","sponsor":"Thomas Chester, OD","startDate":"2020-10-01","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT04631315","phase":"PHASE4","title":"Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery.","status":"COMPLETED","sponsor":"Laboratorios Poen","startDate":"2019-03-24","conditions":"Cataract","enrollment":255},{"nctId":"NCT00335114","phase":"NA","title":"Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2005-11","conditions":"Contact Lens Wearers With Dry Eye Syndrome","enrollment":40},{"nctId":"NCT04735510","phase":"PHASE3","title":"Novel Use of Restasis and PROSE Devices","status":"WITHDRAWN","sponsor":"Boston Sight","startDate":"2021-05","conditions":"Ocular Surface Disease","enrollment":""},{"nctId":"NCT04812951","phase":"EARLY_PHASE1","title":"Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2021-02-17","conditions":"Ocular Surface Disease, Ocular Inflammation","enrollment":101},{"nctId":"NCT05689996","phase":"PHASE3","title":"Ozone-based Eye Drops as Adjuvant Therapy in Microbial Keratitis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-01","conditions":"Keratitis","enrollment":40},{"nctId":"NCT04687800","phase":"PHASE4","title":"Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery","status":"TERMINATED","sponsor":"Cathleen McCabe MD","startDate":"2020-12-01","conditions":"Cataract","enrollment":1},{"nctId":"NCT04127851","phase":"PHASE4","title":"Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2019-11-12","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":438},{"nctId":"NCT01751126","phase":"PHASE3","title":"Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2013-04-29","conditions":"Vernal Keratoconjunctivitis","enrollment":169},{"nctId":"NCT05245604","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2020-06-19","conditions":"Dry Eye Syndrome","enrollment":182},{"nctId":"NCT03626376","phase":"PHASE4","title":"Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2019-12-10","conditions":"Herpes Simplex Virus Keratitis","enrollment":""},{"nctId":"NCT00328653","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2006-05","conditions":"Conjunctivitis, Vernal","enrollment":118},{"nctId":"NCT03597139","phase":"PHASE2","title":"Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2018-08-13","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT04900129","phase":"PHASE1","title":"Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study","status":"COMPLETED","sponsor":"Sher-E-Bangla Medical College","startDate":"2020-12-01","conditions":"Covid19","enrollment":43},{"nctId":"NCT01939691","phase":"PHASE4","title":"Macular Edema Nepafenac vs. Difluprednate Uveitis Trial","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2018-09-12","conditions":"Uveitis, Macular Edema","enrollment":9},{"nctId":"NCT04636918","phase":"PHASE4","title":"Ikervis for DED Due to GVHD Post Allo-HSCT","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2019-11-28","conditions":"Leukemia (Both ALL and AML), MDS-EB-1","enrollment":40},{"nctId":"NCT02004067","phase":"PHASE4","title":"Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2013-01","conditions":"Primary Sjogren Syndrome, Secondary Sjogren Syndrome, Aqueous Deficient Dry Eye Disease","enrollment":100},{"nctId":"NCT03676335","phase":"PHASE2","title":"Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2018-05-09","conditions":"Dry Eye","enrollment":240},{"nctId":"NCT02199964","phase":"NA","title":"The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2014-03","conditions":"Dry Eye","enrollment":4},{"nctId":"NCT03569202","phase":"NA","title":"Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2018-05-21","conditions":"Dry Eye Syndrome","enrollment":64},{"nctId":"NCT03693989","phase":"PHASE3","title":"Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2018-10-04","conditions":"Cataract","enrollment":178},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT01817582","phase":"PHASE2","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05-17","conditions":"Keratoconjunctivitis Sicca","enrollment":102},{"nctId":"NCT03492541","phase":"NA","title":"Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2018-07-18","conditions":"Dry Eye Disease","enrollment":134},{"nctId":"NCT00827255","phase":"","title":"Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Dry Eye Disease","enrollment":35},{"nctId":"NCT02121847","phase":"PHASE4","title":"Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT03666884","phase":"PHASE4","title":"The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Seref istek","startDate":"2015-10-10","conditions":"Dry Eye Syndrome","enrollment":36},{"nctId":"NCT03517748","phase":"NA","title":"Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness","status":"COMPLETED","sponsor":"Horus Pharma","startDate":"2016-12-01","conditions":"Dry Eye","enrollment":80},{"nctId":"NCT03331770","phase":"PHASE4","title":"Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost","status":"COMPLETED","sponsor":"Laboratorios Poen","startDate":"2017-01-06","conditions":"Primary Open-angle Glaucoma","enrollment":103},{"nctId":"NCT02554981","phase":"PHASE4","title":"Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-07-21","conditions":"Dry Eye Syndromes","enrollment":51},{"nctId":"NCT00755040","phase":"PHASE3","title":"Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2008-10","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":164},{"nctId":"NCT01198782","phase":"PHASE4","title":"Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Dry Eye Syndrome","enrollment":48},{"nctId":"NCT01066988","phase":"NA","title":"Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-01","conditions":"Dry Eye","enrollment":40},{"nctId":"NCT00739349","phase":"PHASE2","title":"NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2008-08","conditions":"Dry Eye","enrollment":132},{"nctId":"NCT01254370","phase":"PHASE2","title":"Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension, Ocular Surface Disease","enrollment":105},{"nctId":"NCT01319773","phase":"PHASE1","title":"Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Dry Eye Syndromes","enrollment":44},{"nctId":"NCT02461719","phase":"PHASE3","title":"Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2014-01","conditions":"Dry Eye Syndromes","enrollment":158},{"nctId":"NCT00665106","phase":"PHASE1","title":"Safety and Tolerability of NOVA63035 \"Corticosteroid\" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2008-04","conditions":"Diabetic Macular Edema","enrollment":20},{"nctId":"NCT02114073","phase":"PHASE2","title":"Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure","status":"COMPLETED","sponsor":"Mashhad University of Medical Sciences","startDate":"2014-04","conditions":"Glaucoma, Open Angle","enrollment":40},{"nctId":"NCT02139033","phase":"PHASE4","title":"A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Ocusoft, Inc.","startDate":"2014-05","conditions":"Keratoconjunctivitis Sicca","enrollment":42},{"nctId":"NCT01718028","phase":"NA","title":"The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Dry Eye","enrollment":51},{"nctId":"NCT00986427","phase":"PHASE2","title":"Restasis for Treatment of Brittle Nails","status":"COMPLETED","sponsor":"Julian M. Mackay-Wiggan","startDate":"2009-07","conditions":"Brittle Nails","enrollment":24},{"nctId":"NCT01124045","phase":"PHASE3","title":"Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-08","conditions":"Cataracts, Inflammation","enrollment":80},{"nctId":"NCT01276223","phase":"PHASE2","title":"Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Dry Eye Disease","enrollment":722},{"nctId":"NCT01201798","phase":"PHASE3","title":"Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Endogenous Anterior Uveitis","enrollment":111},{"nctId":"NCT01244334","phase":"PHASE4","title":"Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.","status":"COMPLETED","sponsor":"Edward J. Holland","startDate":"2009-03","conditions":"Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration","enrollment":52},{"nctId":"NCT00824811","phase":"PHASE2","title":"Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06","conditions":"Epiphora","enrollment":""},{"nctId":"NCT01109056","phase":"PHASE2","title":"Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Pterygium","enrollment":115},{"nctId":"NCT00983203","phase":"NA","title":"Acute Comfort and Haze Profile of FID 114657","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-07","conditions":"Dry Eye","enrollment":20},{"nctId":"NCT01079858","phase":"NA","title":"Evaluation of FID 114657 in Dry Eye Subjects","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-02","conditions":"Meibomian Gland Dysfunction","enrollment":49},{"nctId":"NCT01368198","phase":"NA","title":"Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Dry Eye","enrollment":50},{"nctId":"NCT01079871","phase":"NA","title":"Evaluation of FID 114657 in Sjogren's Syndrome Subjects","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-02","conditions":"Sjogren's Syndrome","enrollment":50},{"nctId":"NCT00717418","phase":"","title":"Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2004-09","conditions":"Keratoconjunctivitis Sicca","enrollment":781},{"nctId":"NCT00611403","phase":"PHASE2","title":"Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-12","conditions":"Dry Eye Syndromes","enrollment":137},{"nctId":"NCT01384851","phase":"NA","title":"Efficacy of the Chronic Application of Tear Formulations","status":"UNKNOWN","sponsor":"Glasgow Caledonian University","startDate":"2011-07","conditions":"Dry Eye","enrollment":38},{"nctId":"NCT00025818","phase":"PHASE3","title":"Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Allergan","startDate":"2001-05","conditions":"Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic","enrollment":290},{"nctId":"NCT00705510","phase":"PHASE4","title":"Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-05","conditions":"Meibomian Gland Dysfunction","enrollment":70},{"nctId":"NCT00814515","phase":"PHASE3","title":"Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2007-09","conditions":"Moderate to Severe Dry Eye Syndrome","enrollment":482},{"nctId":"NCT00349440","phase":"PHASE4","title":"Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2006-09","conditions":"Dry Eye Syndromes","enrollment":93},{"nctId":"NCT00704275","phase":"PHASE4","title":"Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2007-06","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT00001731","phase":"PHASE2","title":"Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1997-11","conditions":"Keratoconjunctivitis Sicca, Sjogren's Syndrome","enrollment":30},{"nctId":"NCT00407225","phase":"PHASE2","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"1999-12","conditions":"Inflammation","enrollment":24},{"nctId":"NCT00406341","phase":"PHASE3","title":"Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2004-04","conditions":"Inflammation","enrollment":200},{"nctId":"NCT00406497","phase":"PHASE2","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2003-04","conditions":"Inflammation","enrollment":24},{"nctId":"NCT00407056","phase":"PHASE3","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2002-08","conditions":"Uveitis, Panuveitis","enrollment":20},{"nctId":"NCT00406887","phase":"PHASE3","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2002-08","conditions":"Anterior Uveitis, Panuveitis","enrollment":140},{"nctId":"NCT00405496","phase":"PHASE2","title":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis","status":"COMPLETED","sponsor":"Sirion Therapeutics, Inc.","startDate":"2000-03","conditions":"Anterior Uveitis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"VISION BLURRED"},{"count":2,"reaction":"CONJUNCTIVAL EROSION"},{"count":2,"reaction":"DISEASE PROGRESSION"},{"count":2,"reaction":"DIZZINESS"},{"count":2,"reaction":"EYE IRRITATION"},{"count":2,"reaction":"FALL"},{"count":2,"reaction":"FEELING HOT"},{"count":2,"reaction":"INSOMNIA"},{"count":2,"reaction":"MOOD ALTERED"}],"_approvalHistory":[{"date":"20221116","type":"ORIG","sponsor":"DR REDDYS","applicationNumber":"ANDA214894"}],"publicationCount":151,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ophthalmic Emulsion","genericName":"Ophthalmic Emulsion","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ophthalmic Emulsion is a small molecule formulation used to treat various eye conditions, including Pterygium, Dry Eye Syndrome, Ocular Discomfort, Open-Angle Glaucoma or Ocular Hypertension, and Ocular Surface Disease. It is available in different concentrations, including 0.1%, and has been studied in clinical trials, such as NCT05456425, for its safety and efficacy.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-11-16T00:00:00.000Z","mah":"DR REDDYS","brand_name_local":null,"application_number":"ANDA214894"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}